wirklich so übertrieben, da keine signifikante Verbesserung , dazu nicht soviel Kap.
um wirklich alleine eine P3 stemmen zu können...
Bounce wird bestimmt kommen, aber halt kein Long ;-) m.p.M
Treatment with Gencaro failed to demonstrate a treatment benefit over and above the active control metoprolol succinate (TOPROL-XL). In U.S. patients, there was a trend for supporting the superiority of Gencaro (30% less risk in recurrence of AF) but it was not statistically significant.
The company says the study was not powered to conventional significance for the primary endpoint but instead use Bayesian statistical modeling of predictive probability of success if the study had 620 subjects with 330 primary events (actual enrollment was 267 with 143 primary events).
seekingalpha.com/news/...underwhelming-mid-stage-gencaro-data